摘要
目的:比较多西他赛联合氟尿嘧啶、顺铂方案与多西他赛联合氟尿嘧啶、洛铂方案治疗晚期不可手术胃癌患者的疗效和不良反应。方法:回顾性分析2015年2月至2018年6月126例晚期不可手术的胃癌患者。洛铂组55例:多西他赛+氟尿嘧啶+洛铂,顺铂组71例:多西他赛+氟尿嘧啶+顺铂。洛铂组和顺铂组均21天为一个疗程,连续治疗四个疗程。结果:洛铂组患者客观有效率为50.91%,顺铂组为35.21%,差异无统计学意义(P>0.05)。洛铂组患者疾病控制率达到83.64%,顺铂组为67.61%,差异有统计学意义(P<0.05)。洛铂组患者在恶心、呕吐、白细胞减少和四肢麻木方面发生率明显低于顺铂组,差异有统计学意义(P<0.05)。洛铂组患者血小板减少发生率高于顺铂组,差异有统计学意义(P<0.05)。洛铂组患者严重不良反应的发生率为21.82%,顺铂组为39.44%,差异具有统计学意义(P<0.05)。结论:将多西他赛联合氟尿嘧啶、顺铂方案中的顺铂以洛铂替代,取得了更好的疾病控制率,而患者的不良反应更轻,严重不良反应的发生率也更低,值得临床进一步研究。
Objective:To compare the efficacy and side effects of docetaxel+fluorouracil+cisplatin regimen and docetaxel+fluorouracil+lobaplatin regimen in the treatment of advanced non-operative gastric cancer.Methods:From February 2015 to June 2018,126 patients with advanced gastric cancer who were not operable were analyzed retrospectively,including lobaplatin group 55 cases(docetaxel+fluorouracil+lobaplatin)and cisplatin group 71 cases(docetaxel+fluorouracil+cisplatin).The two groups were treated for 21 days for a course of treatment,and continuous treatment for four courses.Results:The objective response rate was 50.91%in lobaplatin group and 35.21%in cisplatin group,with no significant difference(P>0.05).The disease control rate of lobaplatin group was 83.64%,and that of cisplatin group was 67.61%.The difference was statistically significant(P<0.05).The nausea,vomiting,leukopenia and limb numbness in lobaplatin group were significantly less than those in cisplatin group(P<0.05).The incidence of thrombocytopenia in patients with lobaplatin group was higher than that in cisplatin group,and the difference was statistically significant(P<0.05).The incidence of severe adverse reactions was 21.82%in lobaplatin group and 39.44%in cisplatin group(P<0.05).Conclusion:Lobaplatin was used to replace cisplatin in docetaxel+fluorouracil+cisplatin regimen,and the disease control rate was better,and the side effects of patients were lighter,the incidence of serious adverse reactions was lower,which is worthy of further clinical study.
作者
王勇
李国苗
李志斌
钟世寿
Wang Yong;Li Guomiao;Li Zhibin;Zhong Shishou(The Second People's Hospital of Neijiang,Sichuan Neijiang 641000,China)
出处
《现代肿瘤医学》
CAS
2020年第10期1712-1714,共3页
Journal of Modern Oncology
关键词
多西他赛
氟尿嘧啶
顺铂
洛铂
胃癌
docetaxel
fluorouracil
cisplatin
lobaplatin
gastric cancer
